A Randomised, Double-Blind, Placebo-controlled Study of Glypromate® in Patients Undergoing Cardiopulmonary Bypass Surgery, evaluating the efficacy of Glypromate® compared to placebo in the reduction of cognitive decline and comparative levels in functional activities of daily living in these patients.

Trial Profile

A Randomised, Double-Blind, Placebo-controlled Study of Glypromate® in Patients Undergoing Cardiopulmonary Bypass Surgery, evaluating the efficacy of Glypromate® compared to placebo in the reduction of cognitive decline and comparative levels in functional activities of daily living in these patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Glycine-proline-glutamate (Primary)
  • Indications Cognition disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms SNUG-2
  • Sponsors Neuren Pharmaceuticals
  • Most Recent Events

    • 08 May 2009 New source identified and integrated (Australian New Zealand Clinical Trials Registry).
    • 11 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top